On November 18, SELLAS Life Sciences Group Inc. fell 11.54% in Pre-Market Trading, trading at $17.15/share, with turnover of $216 thousand.
The move followed the company’s announcement that it has commenced an underwritten public offering of $150 million of common stock, with underwriters granted a 30-day option to purchase up to an additional $22.5 million of shares, a transaction that points to meaningful near-term dilution.
The financing came immediately after SELLAS Life Sciences Group Inc. surged on positive phase 3 REGAL data for galinpepimut-S in acute myeloid leukemia. The company said the vaccine met the primary endpoint, improved median overall survival to 24 months from 14.7 months, and reduced the risk of death by 41%, while it prepares discussions with the FDA on an accelerated filing strategy. The new equity raise appears to be the clearest catalyst behind the latest pre-market weakness.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments